Molecular Simulations Identify Target Receptor Kinases Bound by Astaxanthin to Induce Breast Cancer Cell Apoptosis

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 367

This Paper With 11 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_ARCHB-7-2_009

تاریخ نمایه سازی: 24 خرداد 1400

Abstract:

Background: We investigated molecular mechanisms behind astaxanthinmediatedinduction of apoptosis in breast cancer cell lines toward combinationtherapy against cancer drug resistance. Methods: Breast cancer cell lines were treated with serial concentrations ofastaxanthin to determine its IC۵۰. We used drug-design software to predictinteractions between astaxanthin and receptor tyrosine kinases or other key geneproducts involved in intracellular signaling pathways. Changes in gene expressionwere examined using RT-PCR. The effect of astaxanthin-nanocarbonscombinations on cancer cells was also evaluated. Results: Astaxanthin induced cell death in all three breast cancer cell lines wasexamined so that its IC۵۰ in two HER۲-amplifying lines SKBR۳ and BT-۴۷۴stood, respectively, at ۳۶ and ۳۷ μM; however, this figure for MCF-۷ wassignificantly lowered to ۲۳ μM (P<۰.۰۵). Astaxanthin-treated SKBR۳ cellsshowed apoptotic death upon co-staining. Our in silico examinations showed thatsome growth-promoting molecules are strongly bound by astaxanthin via theirspecific amino acid residues with their binding energy standing below -۶KCa/Mol. Next, astaxanthin was combined with either graphene oxide orcarboxylated multi-walled carbon nanotube, with the latter affecting SKBR cellsurvival more extensively than the former (P<۰.۰۵). Finally, astaxanthin coinducedtumor suppressors p۵۳ and PTEN but downregulated the expression ofgrowth-inducing genes in treated cells.Conclusions: These findings indicate astaxanthin carries' multitarget antitumorigeniccapacities and introduce the compound as a suitable candidate forcombination therapy regimens against cancer growth and drug resistance.Development of animal models to elucidate interactions between the compoundand tumor microenvironment could be a major step forward towards the inclusionof astaxanthin in cancer therapy trials.

Authors

Mossa Gardaneh

Department of Stem Cells and Regenerative Medicine, Division of Medical Biotechnology, National Institute ofGenetic Engineering and Biotechnology, Tehran, Iran

Zahra Nayeri

Department of Stem Cells and Regenerative Medicine, Division of Medical Biotechnology, National Institute ofGenetic Engineering and Biotechnology, Tehran, Iran

Parvin Akbari

Department of Stem Cells and Regenerative Medicine, Division of Medical Biotechnology, National Institute ofGenetic Engineering and Biotechnology, Tehran, Iran

Mahsa Gardaneh

Department of Biology, York University, Toronto, Canada

Hasan Tahermansouri

Department of Chemistry, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran